At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 13 enrolled
Drug / intervention
SOR007 Ointment 2.0% +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Randomized, Placebo and Active Comparator-controlled Trial, Double-blind for the IPs, Observer-blind for the Active Comparator, to Assess the Potency of SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment in a Psoriasis Plaque Test
In Brief
A Phase 1 clinical trial evaluating SOR007 Ointment 2.0%, SOR007 Ointment 1.0%, and 4 other interventions for Plaque Psoriasis. Completed, enrolled 13 participants across 2 sites.
Detailed Summary
Evaluation of safety, pharmacokinetics, and anti-psoriatic efficacy to assess SOR007 Ointment in topical formulations
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesUnited States
CollaboratorsBioskin GmbH, US Biotest, Inc.
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartAug 2016
First PostedDec 2016
Primary CompletionFeb 2017
TodayJul 2026
First PostedDec 28, 2016
Enrollment StartAug 1, 2016
Primary CompletionFeb 13, 2017
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 9.5 years ago
Interventions
SOR007 Ointment 2.0%drug
SOR007 Ointment 1.0%drug
SOR007 Ointment 0.3%drug
SOR007 Ointment 0.15%drug
SOR007 Ointment Placebodrug
Taclonex® Ointmentdrug